Maryland State Retirement & Pension System purchased a new position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Free Report) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 14,425 shares of the company’s stock, valued at approximately $2,032,000.
Several other large investors have also recently made changes to their positions in PTGX. BlackRock Inc. purchased a new stake in shares of Protagonist Therapeutics during the second quarter worth approximately $1,263,535,000. Janus Henderson Group PLC lifted its holdings in Protagonist Therapeutics by 9.1% in the 1st quarter. Janus Henderson Group PLC now owns 2,891,527 shares of the company’s stock valued at $304,866,000 after purchasing an additional 241,546 shares in the last quarter. Johnson & Johnson purchased a new position in Protagonist Therapeutics in the 2nd quarter valued at $300,220,852. Jupiter Topco LLC purchased a new position in Protagonist Therapeutics in the 2nd quarter valued at $261,039,000. Finally, Bank of America Corp DE purchased a new position in Protagonist Therapeutics in the 2nd quarter valued at $162,357,000. 98.63% of the stock is currently owned by hedge funds and other institutional investors.
Protagonist Therapeutics Stock Down 2.6%
Shares of Protagonist Therapeutics stock traded down $3.43 on Friday, hitting $130.95. 759,914 shares of the company were exchanged, compared to its average volume of 614,125. The company has a 50-day moving average price of $140.30 and a 200 day moving average price of $119.11. The stock has a market capitalization of $8.55 billion, a price-to-earnings ratio of 27.74 and a beta of 1.21. Protagonist Therapeutics, Inc. has a 1-year low of $77.00 and a 1-year high of $160.81.
Protagonist Therapeutics (NASDAQ:PTGX – Get Free Report) last posted its quarterly earnings results on Thursday, November 5th. The company reported $3.07 EPS for the quarter, beating the consensus estimate of $2.50 by $0.57. Protagonist Therapeutics had a return on equity of 42.83% and a net margin of 62.04%. The firm had revenue of $274.41 million during the quarter, compared to analysts’ expectations of $238.49 million. Research analysts forecast that Protagonist Therapeutics, Inc. will post 5.52 EPS for the current year.
Analyst Upgrades and Downgrades
Several brokerages have issued reports on PTGX. HC Wainwright lifted their target price on shares of Protagonist Therapeutics from $170.00 to $221.00 and gave the stock a “buy” rating in a research note on Friday, November 6th. Barclays increased their target price on shares of Protagonist Therapeutics from $153.00 to $180.00 and gave the company an “overweight” rating in a research report on Tuesday, September 1st. Wedbush reiterated an “outperform” rating on shares of Protagonist Therapeutics in a research report on Monday, November 9th. Wall Street Zen downgraded shares of Protagonist Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Sunday. Finally, UBS Group reissued a “buy” rating on shares of Protagonist Therapeutics in a research note on Tuesday, November 3rd. One equities research analyst has rated the stock with a Strong Buy rating and sixteen have assigned a Buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Buy” and an average price target of $166.67.
Insiders Place Their Bets
In other Protagonist Therapeutics news, CEO Dinesh V. Ph D. Patel sold 63,548 shares of the company’s stock in a transaction on Wednesday, September 9th. The stock was sold at an average price of $146.18, for a total value of $9,289,446.64. Following the completion of the sale, the chief executive officer directly owned 522,968 shares in the company, valued at $76,447,462.24. This represents a 10.83% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Asif Ali sold 58,629 shares of the firm’s stock in a transaction on Wednesday, September 30th. The stock was sold at an average price of $141.78, for a total value of $8,312,419.62. Following the completion of the sale, the chief financial officer directly owned 59,003 shares of the company’s stock, valued at $8,365,445.34. This trade represents a 49.84% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 183,629 shares of company stock worth $26,552,987 in the last three months. 5.19% of the stock is currently owned by corporate insiders.
Protagonist Therapeutics Profile
Protagonist Therapeutics is a clinical-stage biopharmaceutical company that discovers and develops peptide-based medicines, primarily for inflammatory and blood disorders. Its research approach uses engineered peptides designed to act on specific biological targets. The company’s programs include rusfertide, a hepcidin mimetic being developed for polycythemia vera, and icotrokinra, an oral interleukin-23 receptor antagonist being developed for immune-mediated diseases. Protagonist has entered into licensing and development collaborations for these programs with Takeda and Johnson & Johnson, respectively; they are investigational medicines, not approved treatments.
Further Reading
- Five stocks we like better than Protagonist Therapeutics
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
- Is It Too Late to Buy the Dip? 3 Corners of the Market Still Offering Real Value
Want to see what other hedge funds are holding PTGX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Free Report).
Receive News & Ratings for Protagonist Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protagonist Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
